Evidence map›Paper›PMID 32461366›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.

Sara Borghi, Stylianos Bournazos, Natalie K Thulin, Chao Li, Anna Gajewski, Robert W Sherwood, Sheng Zhang, Eva Harris, Prasanna Jagannathan, Lai-Xi Wang and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 83 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Targeting FcRn for immunomodulation: a promising therapy in autoimmune inflammatory rheumatic diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Human antibodies against West Nile and related orthoflaviviruses.bioRxiv : the preprint server for biology · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Antibody glycosylation in neuroimmune diseases.Journal of translational medicine · 2025
    Review
  18. Article
  19. Article
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Sara BorghiThe Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065.ORCID 0000-0001-5473-3240
Stylianos BournazosThe Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065.
Natalie K ThulinDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Chao LiDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742.
Anna GajewskiSustainable Sciences Institute, Managua 14007, Nicaragua.
Robert W SherwoodProteomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853.
Sheng ZhangProteomics Facility, Institute of Biotechnology, Cornell University, Ithaca, NY 14853.
Eva HarrisSchool of Public Health, University of California, Berkeley, CA 94720.ORCID 0000-0002-7238-4037
Prasanna JagannathanDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305.
Lai-Xi WangDepartment of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742.ORCID 0000-0003-4293-5819
Jeffrey V RavetchThe Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY 10065; ravetch@rockefeller.edu taiawang@stanford.edu.ORCID 0000-0003-2024-9041
Taia T WangDepartment of Medicine, Stanford University School of Medicine, Stanford, CA 94305; ravetch@rockefeller.edu taiawang@stanford.edu.ORCID 0000-0002-3894-685X
Rockefeller University · USCornell University · USStanford University · USUniversity of Maryland, College Park · USChan Zuckerberg Initiative (United States) · USSustainable Sciences Institute · USUniversity of California, Berkeley · US

Funding

Project 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FERNANDEZ-SESMA, ANA, HARRIS, EVA · 2015 to 2021
$46.6M
Optimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M
Regulation of the IgG Fc domain repertoireR01AI139119 · NIAID · STANFORD UNIVERSITY · PI WANG, TAIA · 2019 to 2023
$2.8M
Synthesis and Function of Antibody Fc Domain GlycoformsR01GM096973 · NIGMS · UNIV OF MARYLAND, COLLEGE PARK · PI WANG, LAI-XI · 2011 to 2020
$2.4M
Basic Training at the Intersection of Innate and Adaptive Immunity in DiseaseT32AI106677 · NIAID · UNIVERSITY OF WASHINGTON · PI GALE, MICHAEL, GOVERMAN, JOAN M · 2013 to 2022
$2.1M
NIAID NIH HHS R01 AI129795NIAID NIH HHS R01 AI139119NIAID NIH HHS T32 AI106677NIAID NIH HHS U19 AI118610NIGMS NIH HHS R01 GM096973
6 · The paper itself

Abstract

The IgG Fc domain has the capacity to interact with diverse types of receptors, including the neonatal Fc receptor (FcRn) and Fcγ receptors (FcγRs), which confer pleiotropic biological activities. Whereas FcRn regulates IgG epithelial transport and recycling, Fc effector activities, such as antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis, are mediated by FcγRs, which upon cross-linking transduce signals that modulate the function of effector leukocytes. Despite the well-defined and nonoverlapping functional properties of FcRn and FcγRs, recent studies have suggested that FcγRs mediate transplacental IgG transport, as certain Fc glycoforms were reported to be enriched in fetal circulation. To determine the contribution of FcγRs and FcRn to the maternal-fetal transport of IgG, we characterized the IgG Fc glycosylation in paired maternal-fetal samples from patient cohorts from Uganda and Nicaragua. No differences in IgG1 Fc glycan profiles and minimal differences in IgG2 Fc glycans were noted, whereas the presence or absence of galactose on the Fc glycan of IgG1 did not alter FcγRIIIa or FcRn binding, half-life, or their ability to deplete target cells in FcγR/FcRn humanized mice. Modeling maternal-fetal transport in FcγR/FcRn humanized mice confirmed that only FcRn contributed to transplacental transport of IgG; IgG selectively enhanced for FcRn binding resulted in enhanced accumulation of maternal antibody in the fetus. In contrast, enhancing FcγRIIIa binding did not result in enhanced maternal-fetal transport. These results argue against a role for FcγRs in IgG transplacental transport, suggesting Fc engineering of maternally administered antibody to enhance only FcRn binding as a means to improve maternal-fetal transport of IgG.

Indexed as

AnimalsFemaleFetal BloodHistocompatibility Antigens Class IHumansImmunoglobulin GMaternal-Fetal ExchangeMiceMice, TransgenicPlacental CirculationPregnancyRandomized Controlled Trials as TopicReceptors, FcReceptors, IgGFc receptor, neonatalHistocompatibility Antigens Class IImmunoglobulin GReceptors, FcReceptors, IgGFc domainFcRnIgGimmunoglobulinplacental transfer

Identifiers

PMID32461366
PMCPMC7293622
OpenAlexW3029342826

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.